Cancer-Selective Treatment of Cancerous and Non-Cancerous Human Cervical Cell Models by a Non-Thermally Operated Electrosurgical Argon Plasma Device.
cancer selectivity
cervical cancer treatment
cervical intraepithelial neoplasia
cold atmospheric plasma (CAP)
free radicals
high frequency electrosurgery
non-thermal plasma
plasma treatment
reactive species
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Apr 2020
23 Apr 2020
Historique:
received:
21
03
2020
revised:
17
04
2020
accepted:
19
04
2020
entrez:
29
4
2020
pubmed:
29
4
2020
medline:
29
4
2020
Statut:
epublish
Résumé
Cold atmospheric plasma (CAP) treatment is developing as a promising option for local anti-neoplastic treatment of dysplastic lesions and early intraepithelial cancer. Currently, high-frequency electrosurgical argon plasma sources are available and well established for clinical use. In this study, we investigated the effects of treatment with a non-thermally operated electrosurgical argon plasma source, a Martin Argon Plasma Beamer System (MABS), on cell proliferation and metabolism of a tissue panel of human cervical cancer cell lines as well as on non-cancerous primary cells of the cervix uteri. Similar to conventional CAP sources, we were able to show that MABS was capable of causing antiproliferative and cytotoxic effects on cervical squamous cell and adenocarcinoma as well as on non-neoplastic cervical tissue cells due to the generation of reactive species. Notably, neoplastic cells were more sensitive to the MABS treatment, suggesting a promising new and non-invasive application for in vivo treatment of precancerous and cancerous cervical lesions with non-thermally operated electrosurgical argon plasma sources.
Identifiants
pubmed: 32340164
pii: cancers12041037
doi: 10.3390/cancers12041037
pmc: PMC7226384
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medizinischen Fakultät, Eberhard Karls Universität Tübingen
ID : 2432-1-0
Organisme : Medizinischen Fakultät, Eberhard Karls Universität Tübingen
ID : 417-0-0
Références
PLoS One. 2011;6(11):e28154
pubmed: 22140530
Nutrients. 2019 Aug 16;11(8):
pubmed: 31426306
Anticancer Res. 2017 Dec;37(12):6739-6744
pubmed: 29187451
ACS Appl Mater Interfaces. 2019 Jun 5;11(22):19841-19853
pubmed: 31071258
BMC Cancer. 2012 Oct 15;12:473
pubmed: 23066891
PLoS One. 2015 Jul 01;10(7):e0130350
pubmed: 26132846
PLoS One. 2013 Sep 11;8(9):e73741
pubmed: 24040051
Biointerphases. 2015 Dec 22;10(4):040801
pubmed: 26700469
Cancers (Basel). 2020 Jan 22;12(2):
pubmed: 31979067
Sci Rep. 2017 Mar 31;7:45781
pubmed: 28361987
Anticancer Res. 2018 Oct;38(10):5655-5663
pubmed: 30275184
Tumour Biol. 2016 Jun;37(6):7021-31
pubmed: 26888782
Free Radic Biol Med. 2017 Sep;110:280-290
pubmed: 28666851
Cancers (Basel). 2019 Jul 22;11(7):
pubmed: 31336648
Endosc Surg Allied Technol. 1994 Feb;2(1):71-7
pubmed: 8081921
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Springerplus. 2014 Jul 31;3:398
pubmed: 25184103
Biochim Biophys Acta. 2014 May;1840(5):1596-604
pubmed: 24060746
Biochem Pharmacol. 2019 Dec 17;:113769
pubmed: 31862448
Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15681-6
pubmed: 20724658
Biochim Biophys Acta. 2006 Aug;1758(8):1034-42
pubmed: 16872579
Onco Targets Ther. 2016 Sep 28;9:5911-5917
pubmed: 27729800
Oxid Med Cell Longev. 2019 Sep 3;2019:3873928
pubmed: 31565150
Exp Dermatol. 2013 Apr;22(4):284-9
pubmed: 23528215
PLoS One. 2013 Dec 18;8(12):e81576
pubmed: 24367486
PLoS One. 2013 May 21;8(5):e64498
pubmed: 23704990
Anticancer Res. 2017 Oct;37(10):5407-5414
pubmed: 28982850
Int J Cancer. 2012 May 1;130(9):2185-94
pubmed: 21702038
Oncotarget. 2017 Feb 28;8(9):15977-15995
pubmed: 27845910